Biohaven reports positive topline results from pivotal migraine trial of intranasal zavegepant demonstrating ultra-rapid pain relief by 15 minutes; prepares for submission of new drug application

New haven, conn., dec. 6, 2021 /prnewswire/ -- biohaven pharmaceutical holding company ltd.

BHVN Ratings Summary

BHVN Quant Ranking